OR WAIT null SECS
March 21, 2023
BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.
March 17, 2023
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.
March 03, 2023
Advancements in therapeutic modalities are necessitating change in drug delivery to help negate some of the expense of development and manufacturing.
February 16, 2023
To prepare for emerging mRNA technologies, it is necessary to adapt fill/finish and cold chain capabilities.
January 11, 2023
This self-emulsifying system improves the miscibility and dispersibility of formulations in aqueous environments and may improve API solubility.
Epinephrine is a critical medication used during life-threatening conditions that can affect any age and any person.
A REMS document is a part of a REMS required by FDA and establishes the goals and requirements of the REMS.
December 03, 2022
Unique solutions are required to protect inherently unstable messenger RNA.
October 12, 2022
CBER maps modernization plan to handle surge in research and applications.